Mostafa Akbarzadeh-Khiavi

Dr. Mostafa Akbarzadeh-Khiavi

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in BioImpacts
Verified
Journal Article
Open access
ASAzam Safary
Azam Safary
MAMostafa Akbarzadeh-Khiavi
Mostafa Akbarzadeh-Khiavi
RMRahimeh Mousavi
Rahimeh Mousavi
JBJaleh Barar
Jaleh Barar
MRMohammad A Rafi
Mohammad A Rafi
Despite many beneficial outcomes of the conventional enzyme replacement therapy (ERT), several limitations such as the high-cost of the treatment and various inadvertent side effects including the occurrence of an immunological response against the infused enzyme and development of resistance to enzymes persist. These issues may limit the desired therapeutic outcomes of a majority of the lysosomal storage diseases (LSDs). Furthermore, the biodistribution of the recombinant enzymes into the target cells within the central nervous system (CNS), bone, cartilage, cornea, and heart still remain unresolved. All these shortcomings necessitate the development of more effective diagnosis and treatment modalities against LSDs. Taken all, maximizing the therapeutic response with minimal undesired side effects might be attainable by the development of targeted enzyme delivery systems (EDSs) as a promising alternative to the LSDs treatments, including different types of mucopolysaccharidoses (MPSs) as well as Fabry, Krabbe, Gaucher and Pompe diseases.

1 July 2019 in Colloids and Surfaces A: Physicochemical and Engineering Aspects
Verified
Journal Article
Closed access
MAMostafa Akbarzadeh-Khiavi
Mostafa Akbarzadeh-Khiavi
ASAzam Safary
Azam Safary
AAAyuob Aghanejad
Ayuob Aghanejad
JBJaleh Barar
Jaleh Barar
SRSeyed Hossein Rasta
Seyed Hossein Rasta
MSMohammad Hossein Somi
Mohammad Hossein Somi

25 July 2019 in BioImpacts
Verified
Journal Article
Open access
PDF file
MAMostafa Akbarzadeh-Khiavi
Mostafa Akbarzadeh-Khiavi
ASAzam Safary
Azam Safary
JBJaleh Barar
Jaleh Barar
HFHamed Farzi-Khajeh
Hamed Farzi-Khajeh
ABAbolfazl Barzegari
Abolfazl Barzegari
YOYadollah Omidi
Yadollah Omidi
Introduction: Currently, drug-induced reactive oxygen species (ROS) mediating apoptosis pathway have extensively been investigated in designing effective strategies for colorectal cancer (CRC) chemotherapy. Bovine pancreatic ribonuclease A (RNase A) represents a new class of cytotoxic and non-mutagenic enzymes, and has gained more attention as a potential anticancer modality; however, the cytosolic ribonuclease inhibitors (RIs) restrict the clinical application of this enzyme. Nowadays, nanotechnology-based diagnostic and therapeutic systems have provided potential solutions for cancer treatments. Methods: In this study, the gold nanoparticles (AuNPs) were synthesized, stabilized by polyethylene glycol (PEG), functionalized, and covalently conjugated with RNase A. The physicochemical properties of engineered nanobiomedicine (AuNPs-PEG-RNase A) were characterized by scanning electron microscope (SEM), dynamic light scattering (DLS), and UV-vis spectrum. Then, its biological impacts including cell viability, apoptosis, and ROS production were evaluated in the SW-480 cells. Results: The engineered nanobiomedicine, AuNPs-PEG-RNase A, was found to effectively induce apoptosis in SW-480 cells and result in a significant reduction in cancer cell viability. Besides, the maximum production of ROS was obtained after the treatment of cells with an IC50 dose of AuNPs-PEG-RNase A. Conclusion: Based on the efficient ROS-responsiveness and the anticancer activity of RNase A of the engineered nanomedicine, this nanoscaled biologics may be considered as a potential candidate for the treatment of CRC.

28 September 2019 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
MAMostafa Akbarzadeh-Khiavi
Mostafa Akbarzadeh-Khiavi
ASAzam Safary
Azam Safary
JBJaleh Barar
Jaleh Barar
AAAmir Ajoolabady
Amir Ajoolabady
MSMohammad Hossein Somi
Mohammad Hossein Somi
YOYadollah Omidi
Yadollah Omidi

8 March 2019 in BioImpacts
Verified
Journal Article
Open access
PDF file
MAMostafa Akbarzadeh-Khiavi
Mostafa Akbarzadeh-Khiavi
ASAzam Safary
Azam Safary
MSMohammad Hossein Somi
Mohammad Hossein Somi
Despite rapid advances in diagnostic and treatment approaches, the overall survival rate of cancer has not been improved. Colorectal cancer (CRC) is recognized as the third leading cause of neoplasm-related deaths worldwide, in large part due to its considerable metastasis and drug resistance. For developing new anticancer strategies, rapid progression of multimodal nanomedicines and nanoconjugates has provided promising treatment modalities for effective therapy of cancer. The limitations of cancer chemotherapy might be overcome through the use of such nanosized therapeutics, including nanoconjugates of monoclonal antibodies (mAbs) along with drugs and organic/inorganic nanoparticles. CRC cells express various molecular markers against which mAbs can be designed and used as targeting/therapeutic agents. This editorial highlights the importance of such targeted nanosystems against CRC.

5 November 2019 in Systems Biology in Reproductive Medicine
Verified
Journal Article
Closed access
MAMostafa Akbarzadeh-Khiavi
Mostafa Akbarzadeh-Khiavi
AJAkbar Jalili
Akbar Jalili
ASAzam Safary
Azam Safary
ZGZiba Gharedaghchi
Ziba Gharedaghchi
SMSeyed Kazem Mirinezhad
Seyed Kazem Mirinezhad
SRSeyyed Ali Rahmani
Seyyed Ali Rahmani
Infertility is one of the major health-threatening problems in communities which may lead to psychological problems among couples. Y chromosome abnormalities and microdeletions have recently been considered as one of the male infertility factors. The aim of this study was to evaluate different chromosomal disorders and azoospermia factor b (AZFb), AZFc and AZFd microdeletions in idiopathic non-obstructive oligo or azoospermia infertile men. One hundred infertile (78 azoospermia and 22 oligospermia) and 100 fertile men were included in this study. Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels were evaluated by electrochemiluminescence. Karyotyping was performed according to standard methods and interpreted using the International System for Human Cytogenetic Nomenclature (ISHCN) recommendation. For Y chromosome microdeletion analysis, a multiplex polymerase chain reaction (PCR) was performed using STS primers. Higher FSH (24.32 ± 15.32 versus 8.02 ± 3.37, p < 0.0001) and LH (14.97 ± 8.26 versus 5.42 ± 2.73, p < 0.0001) were observed in infertile patients compared to their fertile counterpart. Additionally, 14% of infertile patients exhibited abnormal karyotype. The frequency of Y chromosome microdeletions in azoospermic and oligospermic patients was 32.05% (25/78) and 0% (0/22), respectively. Additionally, in azoospermic patients, the highest microdeletion frequency was related to the AZFc region (80%). Our data indicate the presence of chromosomal changes in the most infertile men, suggesting karyotype and molecular analysis of Y chromosome microdeletions for genetic counseling before assisted reproduction. Abbreviations: ART: assisted reproductive technology; AZF: azoospermia factor; DAZ: deleted in azoospermia; FCS: fetal calf serum; FSH: follicle stimulating hormone; LH: luteinizing hormone; PCR: polymerase chain reaction; SRY: sex-determining region Y; STS: sequence-tagged sites